Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

BUY
$1.25 - $2.51 $3,126 - $6,277
2,501 Added 41683.33%
2,507 $3,000
Q3 2023

Nov 14, 2023

SELL
$2.15 - $3.59 $32 - $53
-15 Reduced 71.43%
6 $0
Q2 2023

Aug 11, 2023

BUY
$2.52 - $4.0 $52 - $84
21 New
21 $0

Others Institutions Holding LGVN

About Longeveron Inc.


  • Ticker LGVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,925,940
  • Market Cap $12.4M
  • Description
  • Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...
More about LGVN
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.